From Metabolic Syndrome to Cardiovascular–Kidney–Metabolic Syndrome and Systemic Metabolic Disorder: A Call to Recognize the Progressive Multisystemic Dysfunction
Review highlights progression from metabolic syndrome to a comprehensive framework, suggesting integrated care for cardiovascular disease and chronic kidney disease.
Key Points
The review outlines a shift from metabolic syndrome to cardiovascular-kidney-metabolic syndrome, recognizing multisystemic dysfunction.
Emerging models emphasize the need for early intervention and stage-based risk stratification in treating chronic kidney disease and obesity.
Dysfunctional adiposity and ectopic fat play pivotal roles in systemic metabolic disorders and related organ damage.
Novel therapies like SGLT2 inhibitors and GLP-1 receptor agonists may provide critical multiorgan protection against metabolic dysfunction.